Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA DME: Aflibercept for Diabetic Macular Edema
NCT01363440Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2011
- Primary completion
- Jan 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Regeneron Pharmaceuticals. Started May 2011; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01363440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01363440.